Showing results (2941-2950 of 10,080) with videos related to

Sort By:
Pageof 1,008
Current Pharmaceutical Design|January 23, 2026
Combining Serum Pharmacochemistry and Metabolomics to Characterize the Synergistic Compatibility Principle of Polygonati Rhizoma and Angelicae Sinensis Radix for MAFLD MitigationHuan Yang, Lei Zi, Pengquan Wang, et al.
Current Pharmaceutical Design|January 23, 2026
Histone Acetylation Retards the Adipogenic Differentiation of Human Umbilical Cord - Mesenchymal Stem Cells: A Clue for Anti-obesity Approach?Harish C Chandramoorthy, Waleed N Hassan, Vimalanathan ArunPrasanna, et al.
Current Pharmaceutical Design|January 23, 2026
Antiviral Drug Discovery from Typha angustifolia Pollen: Computational Analysis Targeting Flaviviridae Polymerases and Entry ProteinsCheng-Yang Hsieh, Janielle Mari Abadilla, Bor-Yann Chen, et al.
Current Pharmaceutical Design|January 27, 2026
Ethical and Regulatory Challenges in Implementing Personalized Medicine in India: Role of Artificial Intelligence in Overcoming Ethical ChallengesChaitali Agrawal, Vikrant Abbot, Thakur Gurjeet Singh, et al.
Current Pharmaceutical Design|March 27, 2025
Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive ReviewDevesh U Kapoor, Bhupendra G Prajapati, Sankha Bhattacharya, et al.
Current Pharmaceutical Design|March 20, 2025
Surgical Excision Margins in Skin Melanomas with Breslow Thickness Greater than 2 Mm: A Systematic Review and Meta-AnalysisLucas S Floriano, Rafael V Picon, Camila Dagostim, et al.
Current Pharmaceutical Design|March 20, 2025
A Comprehensive Review on Novel Therapies for Gastrointestinal Cancers using Translational PlatformsTrilochan Satapathy, Shiv Kumar Bhardwaj, Arvind Kumar, et al.
Current Pharmaceutical Design|March 20, 2025
Identification of Natural Compounds as Potential COVID-19 Main Protease (Mpro) Inhibitors: A Comprehensive Study and In silico EvidenceArti Devi, Vagish Dwibedi, Sahil Jain, et al.
Current Pharmaceutical Design|April 10, 1999
High density lipoprotein: are elevated levels desirable and achievable?C L Bisgaier, M E Pape
Current Pharmaceutical Design|April 10, 1999
A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancerD J Taatjes, D J Fenick, G Gaudiano, et al.
Pageof 1,008